Ephedrine, continuous infusion — Competitive Intelligence Brief

Ephedrine, continuous infusion (Ephedrine, continuous infusion) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sympathomimetic amine. Area: Cardiovascular.

marketed Sympathomimetic amine Alpha and beta-adrenergic receptors Cardiovascular Small molecule

Target snapshot

Ephedrine, continuous infusion (Ephedrine, continuous infusion) — University of Parma.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ephedrine, continuous infusion TARGET	Ephedrine, continuous infusion	University of Parma	marketed	Sympathomimetic amine	Alpha and beta-adrenergic receptors
Bupivicaine + epinephrine	Bupivicaine + epinephrine	Rush University Medical Center	marketed	Local anesthetic with vasopressor	Voltage-gated sodium channels; alpha and beta-adrenergic receptors
Propadrine	PHENYLPROPANOLAMINE	Alpharma Us Pharms	marketed	Indirectly Acting Sympathomimetic Amines	Sodium-dependent noradrenaline transporter	2000-01-01
Didrex	BENZPHETAMINE	Pfizer	marketed	Sympathomimetic Amine Anorectic	Alpha-1A adrenergic receptor	1960-01-01
Tenuate	DIETHYLPROPION	ANI Pharmaceuticals	marketed	Sympathomimetic Amine Anorectic	Sodium-dependent dopamine transporter	1959-01-01
Aramine	METARAMINOL		marketed	Indirectly Acting Sympathomimetic Amines	Macrophage migration inhibitory factor	1954-01-01
Vialin	MEPHENTERMINE	Baxter	marketed	Indirectly Acting Sympathomimetic Amines	Alpha-1A adrenergic receptor	1951-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sympathomimetic amine class)

1. Dalian Municipal Central Hospital · 1 drug in this class
2. University Tunis El Manar · 1 drug in this class
3. University of Parma · 1 drug in this class